An Ascending, Multiple-Dose, Safety and Tolerability Study of Tecarfarin in Healthy Chinese Volunteers

NCT04627116 | Unknown Phase 1

• 1 other identifier: ZK-TEK-201905
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The subjects will be admitted to the Phase I Clinical Research Center on day -1. Subjects received once-daily doses of Tecarfarin for up to 14 days.Subjects can leave the Phase I Clinical Research Center on the day 21.And returned to the research center for follow-up on the day 28 and 35.

Conditions

Healthy Chinese Volunteers

Outcome Measures

Primary Outcomes (1)

• The primary objective of this study was to evaluate the safety and tolerability of Tecarfarin when administered as rising multiple oral doses to healthy Chinese volunteers.

  Subjects received once-daily doses of Tecarfarin for up to 14 days.

  doses of Tecarfarin for up to 14 days.

Study Arms (4)

Tecarfarin 10mg

EXPERIMENTAL

Drug: Tecarfarin

Tecarfarin 20mg

EXPERIMENTAL

Drug: Tecarfarin

Tecarfarin 30mg

EXPERIMENTAL

Drug: Tecarfarin

Tecarfarin 40mg

EXPERIMENTAL

Drug: Tecarfarin

Interventions

Tecarfarin DRUG

Ten (10) healthy Chinese subjects received once-daily doses of Tecarfarin on fasting every morning for 14 days.

Tecarfarin 10mg; Tecarfarin 20mg; Tecarfarin 30mg; Tecarfarin 40mg

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• \) the subjects were fully aware of the purpose, nature, methods and possible adverse reactions of the trial, voluntarily act as subjects, and sign an informed consent form before the commencement of any research process.
• ）Healthy volunteers between the ages of 18 to 50 years old (inclusive). 3）Weight: male ≥ 50.0kg, female ≥ 45.0kg; Body Mass Index (BMI) ≥19 and ≤ 24 kg/m2.
• \) The physical examination, vital sign measurements, clinical laboratory assessments hematology, clinical chemistry, or urinalysis, etc.) and 12-lead ECG were judged normal, or abnormal without clinical significance by the investigators.

You may not qualify if:

• \. Positive test results for HIV, syphilis antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCV Ab) at Screening.
• \) Dysphagia or documented history of any gastrointestinal disorders that affect drug absorption.
• \) Subjects with difficulty in venipuncture, those who cannot tolerate venipuncture, and those who have a history of needlesickness and bloodsickness.
• \) Positive tests for urine drugs of abuse at Screening or a history of drug or alcohol abuse/dependence.
• \) Use of tobacco products 3 months before screening. 6）Heavy tea, coffee and / or caffeinated drinks (more than 8 cups, 1 cup = 250 mL) drinker per day within 3 months prior to screening.
• ）Subjects who drunk frequently within 6 months prior to screening (intake of more than 14 units of alcohol per week. A unit is 360 mL beer, 45 mL of 40% liquor or 150 mL wine).
• ）Any out-of-normal-range PT, aPTT, TT, FIB,INR, protein C, protein S or coagulation factors II, VII, X at screening.
• ）History of cardiovascular, renal, pulmonary, nervous system, liver and/or endocrine disease.
• ）Documented history of bleeding diathesis, coagulopathy, or inherited disorders of coagulation.
• ）Evidence of active bleeding, including but not limited to gastrointestinal bleeding (hematemesis, hematochezia, positive fecal occult blood), urinary tract bleeding, mucosal bleeding (gingival, epistaxis) and unexplained subcutaneous bleeding or ecchymosis.
• ）Participation in a previous clinical trial within 3 months prior to Screening.
• ）Clinically significant surgical procedure within 4 weeks prior to Screening or planned to undergo surgery during the study period.
• \) Clinically significant blood loss or blood donation \> 550 ml within 3 months prior to Screening.
• ）Taking any medication 14 days prior to Screening. 16）Known allergy or hypersensitivity to warfarin or the investigational product.
• ）Pregnancy or Lactation. 18）Female subjects cannot avoid menstruation during administration. 19）subjects of childbearing age are not guaranteed to have no fertility plan, sperm donation, egg donation plan and voluntary use of non-drug contraceptive measures (including subcutaneous injection of contraceptive, contraceptive injections, subcutaneous implantation of contraceptives, local contraceptives such as spermicide, etc.) from two weeks before screening to 6 months after the end of the trial.

Sponsors & Collaborators

• Lee's Pharmaceutical Limited: lead

Study Sites (1)

The Second Hospital of Anhui Medical University

Hefei, China

Location

Related Publications (1)

• Zhou Q, Wang Z, Wang H, Chen Z, Li X, Dai X, Zhang Y, Yu X, Zhou R, Hu W. Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial. Am J Cardiovasc Drugs. 2023 Jan;23(1):101-112. doi: 10.1007/s40256-022-00562-5. Epub 2023 Jan 9.

  PMID: 36622539 DERIVED

MeSH Terms

Interventions

tecarfarin

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 8, 2020
• First Posted: November 13, 2020
• Study Start: April 19, 2020
• Primary Completion: December 5, 2020
• Study Completion: December 30, 2020
• Last Updated: November 13, 2020

Record last verified: 2020-11

Locations

CN (1)